Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• Bacteria-based therapies show potential for targeted cancer treatment and stimulating anti-tumor immune responses.
• Despite promising preclinical data, some bacterial therapies like Salmonella typhimurium VNP20009 have faced challenges in clinical trials, including limited efficacy and side effects.

Purpose of the Study:

• To review the fundamentals of bacteria-mediated bio-therapy.
• To summarize recent advancements (past 5 years) in bacteria-mediated synergistic cancer therapy (BMSCT), focusing on combinations with traditional modalities.
• To discuss administration routes, benefits, challenges, and future directions for BMSCT.

Main Methods:

• Literature review of bacteria-mediated bio-therapy and BMSCT.
• Analysis of synergistic effects between bacteria and chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, and prodrug-activating therapy.
• Evaluation of different administration routes for BMSCT.

Main Results:

• BMSCT integrates bacterial therapy with conventional treatments to enhance anti-tumor efficacy.
• Combinations with chemotherapy, photothermal therapy, ROS/RNS therapy, immunotherapy, and prodrug therapy show potential benefits.
• Optimized administration routes can potentiate anti-tumor responses while mitigating side effects.

Conclusions:

• BMSCT represents a promising frontier in cancer therapy, leveraging the microbiome for enhanced treatment outcomes.
• Careful consideration of therapeutic combinations and administration routes is crucial for maximizing efficacy and minimizing toxicity.
• Further research and development are needed to fully realize the potential of BMSCT in clinical settings.